Neuphoria Therapeutics Inc. (NEUP) Insider Trading Disclosures
Neuphoria Therapeutics Inc. (NEUP) is a publicly traded company on the Nasdaq, categorized under SIC 2834 (Pharmaceutical Preparations). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: NEUP
CIK: 1191070
Exchange: Nasdaq
SIC 2834: Pharmaceutical Preparations
Fiscal Year End: 06/30
State: C3
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
Wolf & Company, P.C.
Auditor SinceSince 6/30/2024 12:00:00 AM
Lead Engagement PartnerJared Kelly
Audit LocationBoston, Massachusetts, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| SCHEDULE 13G | 2026-10-05 | — | SCHEDULE 13G Filing | 0000929638-26-003845 | View SEC Doc Filr Page |
| DEFA14A | 2026-09-18 | — | DEFA14A | 0001140361-26-037146 | View SEC Doc Filr Page |
| DEFA14A | 2026-09-18 | — | DEFA14A | 0001140361-26-037144 | View SEC Doc Filr Page |
| DEF 14A | 2026-09-18 | 2026-11-02 | DEF 14A | 0001140361-26-037139 | View SEC Doc Filr Page |
| 10-K | 2026-09-18 | 2026-06-30 | 10-K | 0001193125-26-395536 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-07-28 | — | SCHEDULE 13G/A Filing | 0001104659-26-087379 | View SEC Doc Filr Page |
| DEFA14A | 2026-07-24 | — | CURRENT REPORT | 0001213900-26-081054 | View SEC Doc Filr Page |
| 8-K | 2026-07-24 | 2026-07-20 | CURRENT REPORT | 0001213900-26-081052 | View SEC Doc Filr Page |
| 8-K | 2026-05-26 | 2026-05-21 | CURRENT REPORT | 0001213900-26-061028 | View SEC Doc Filr Page |
| 10-Q | 2026-05-15 | 2026-03-31 | 10-Q | 0001193125-26-225442 | View SEC Doc Filr Page |
| 10-Q | 2026-02-17 | 2025-12-31 | 10-Q | 0001193125-26-054509 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-02-06 | — | SCHEDULE 13G/A Filing | 0001957912-26-000007 | View SEC Doc Filr Page |
| 4 | 2026-01-21 | 2026-01-20 | 4 Filing | 0001213900-26-006173 | View SEC Doc Filr Page |
| 4 | 2026-01-21 | 2026-01-20 | 4 Filing | 0001213900-26-006171 | View SEC Doc Filr Page |
| 4 | 2026-01-21 | 2026-01-20 | 4 Filing | 0001213900-26-006172 | View SEC Doc Filr Page |
| 4 | 2026-01-21 | 2026-01-20 | 4 Filing | 0001213900-26-006170 | View SEC Doc Filr Page |
| 8-K | 2026-01-08 | 2025-12-31 | CURRENT REPORT | 0001213900-26-002245 | View SEC Doc Filr Page |
| SCHEDULE 13D/A | 2025-12-29 | — | SCHEDULE 13D/A Filing | 0000905148-25-004490 | View SEC Doc Filr Page |
| 8-K | 2025-12-18 | 2025-12-18 | CURRENT REPORT | 0001213900-25-123289 | View SEC Doc Filr Page |
| 8-K | 2025-12-17 | 2025-12-12 | CURRENT REPORT | 0001213900-25-122777 | View SEC Doc Filr Page |
| DFAN14A | 2025-12-08 | — | DFAN14A | 0001193125-25-311436 | View SEC Doc Filr Page |
| DFAN14A | 2025-12-08 | — | DFAN14A | 0001193125-25-311358 | View SEC Doc Filr Page |
| DEFA14A | 2025-12-08 | — | DEFINITIVE ADDITIONAL MATERIALS | 0001213900-25-119241 | View SEC Doc Filr Page |
| DEFA14A | 2025-12-04 | — | DEFINITIVE ADDITIONAL MATERIALS | 0001213900-25-118291 | View SEC Doc Filr Page |
| DFAN14A | 2025-12-03 | — | DFAN14A | 0001193125-25-305885 | View SEC Doc Filr Page |